- Home
- MODD vs KRON Comparison
MODD vs KRON Comparison
Compare MODD & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- KRON
- Stock Information
- Founded
- MODD 1998
- KRON 2017
- Country
- MODD United States
- KRON United States
- Employees
- MODD N/A
- KRON N/A
- Industry
- MODD Industrial Specialties
- KRON Medicinal Chemicals and Botanical Products
- Sector
- MODD Health Care
- KRON Health Care
- Exchange
- MODD Nasdaq
- KRON Nasdaq
- Market Cap
- MODD 53.0M
- KRON 59.1M
- IPO Year
- MODD N/A
- KRON 2020
- Fundamental
- Price
- MODD $1.21
- KRON $0.99
- Analyst Decision
- MODD Buy
- KRON Buy
- Analyst Count
- MODD 1
- KRON 3
- Target Price
- MODD $5.00
- KRON $1.63
- AVG Volume (30 Days)
- MODD 152.4K
- KRON 292.4K
- Earning Date
- MODD 02-11-2025
- KRON 11-13-2024
- Dividend Yield
- MODD N/A
- KRON N/A
- EPS Growth
- MODD N/A
- KRON N/A
- EPS
- MODD N/A
- KRON N/A
- Revenue
- MODD N/A
- KRON $9,864,000.00
- Revenue This Year
- MODD N/A
- KRON $62.21
- Revenue Next Year
- MODD $862.50
- KRON N/A
- P/E Ratio
- MODD N/A
- KRON N/A
- Revenue Growth
- MODD N/A
- KRON 146.48
- 52 Week Low
- MODD $1.08
- KRON $0.69
- 52 Week High
- MODD $2.65
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- MODD 30.05
- KRON 53.69
- Support Level
- MODD $1.36
- KRON $0.92
- Resistance Level
- MODD $1.34
- KRON $1.02
- Average True Range (ATR)
- MODD 0.09
- KRON 0.05
- MACD
- MODD -0.00
- KRON 0.00
- Stochastic Oscillator
- MODD 15.20
- KRON 77.38
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.